Science Explorer Back to mapMap
Discussion
Topic · Immunology

Biosimilars and Bioanalytical Methods

Biosimilars and Bioanalytical Methods is a research topic within Immunology. Science Explorer counts 17k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the immunogenicity of biosimilar therapeutics, including the validation of bioanalytical methods for assessing immunogenicity, the impact of manufacturing changes on immunogenicity, and the clinical outcomes and safety of switching from reference biologics to biosimilars. The use of dried blood spots for bioanalysis and the regulatory considerations for biosimilars are also prominent topics within this cluster.

  • Biosimilars
  • Immunogenicity
  • Bioanalytical Methods
  • Therapeutic Proteins
  • Dried Blood Spots
  • Erythropoietin Antibodies
  • Monoclonal Antibodies
  • Regulatory Guidelines
  • Biopharmaceuticals
  • Clinical Outcomes
Research works
17k
fractional, since 1950
In the world top 10%
1.7k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+15%
the tick is no change
Largest producer
United States
39% of the 10 largest, 2022-now
Biosimilars and Bioanalytical Methods

Which countries lead Biosimilars and Bioanalytical Methods research?

By volume, the United States and China publish the most (1.3k and 389 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.3k works
  2. 2 China 389 works
  3. 3 United Kingdom 307 works
  4. 4 India 306 works
  5. 5 Germany 240 works
  6. 6 Spain 220 works
  7. 7 France 181 works
  8. 8 Italy 168 works
  9. 9 Japan 138 works
  10. 10 Canada 138 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 39.2%China: 11.3%United Kingdom: 8.9%India: 8.9%6 others listed: 31.6%39%largest
United States1,347 · 39.2%China389 · 11.3%United Kingdom307 · 8.9%India306 · 8.9%6 others listed1,084 · 31.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead Biosimilars and Bioanalytical Methods research?

By volume in 2022-now, Harvard University publishes the most Biosimilars and Bioanalytical Methods research, followed by Pfizer (United States) and Johnson & Johnson (United States).

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 50 works
  2. 2 Pfizer (United States)United States 33 works
  3. 3 Johnson & Johnson (United States)United States 30 works
  4. 4 United States Food and Drug AdministrationUnited States 30 works
  5. 5 Roche (Switzerland)Switzerland 29 works
  6. 6 InsermFrance 26 works
  7. 7 University of North Carolina at Chapel HillUnited States 26 works
  8. 8 Mayo ClinicUnited States 24 works
  9. 9 AstraZeneca (United Kingdom)United Kingdom 22 works
  10. 10 University of TorontoCanada 19 works

Who are the leading researchers in Biosimilars and Bioanalytical Methods?

The most-cited researchers publishing on Biosimilars and Bioanalytical Methods include Gad A. Getz, John J.V. McMurray and Cyrus Cooper.

  1. 1 Gad A. Getz United States 364k citations
  2. 2 John J.V. McMurray United Kingdom 349k citations
  3. 3 Cyrus Cooper United Kingdom 342k citations
  4. 4 Jun Wang China 340k citations
  5. 5 Giuseppe Remuzzi Italy 328k citations
  6. 6 Matthias Egger Switzerland 326k citations
  7. 7 John P. A. Ioannidis United States 317k citations
  8. 8 Gordon Henry Guyatt Canada 315k citations
  9. 9 Dan J. Stein South Africa 306k citations
  10. 10 Peter Christian Gøtzsche Denmark 292k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Biosimilars and Bioanalytical Methods?

The most cited paper in Biosimilars and Bioanalytical Methods is "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update" (Josef S Smolen et al., 2017), with 5,808 citations. Next come "The price of innovation: new estimates of drug development costs" (4,325) and "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial" (4,190).

Most cited papers
#PaperReleasedCitations
1 EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Josef S Smolen et al. · Annals of the Rheumatic Diseases Open access 6 Mar 2017 5,808
2 The price of innovation: new estimates of drug development costs Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski · Journal of Health Economics Open access 28 Feb 2003 4,325
3 Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet May 2002 4,190
4 Can the pharmaceutical industry reduce attrition rates? Ismail Kola, John Richard Landis · Nature Reviews Drug Discovery 30 Jul 2004 4,181
5 A rapid method for the isolation of functional thymus‐derived murine lymphocytes Michael H. Julius, Elizabeth Simpson, L A Herzenberg · European Journal of Immunology Oct 1973 4,167
All 100 most cited papers, with filters and sorting

Where is Biosimilars and Bioanalytical Methods research done?

The largest centres of Biosimilars and Bioanalytical Methods research in 2022-now are London (United Kingdom), New York (United States), Beijing (China) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Silver Spring.

Largest cities, 2022-now

  1. 1 LondonUnited Kingdom 100 works
  2. 2 New YorkUnited States 89 works
  3. 3 BeijingChina 72 works
  4. 4 ParisFrance 61 works
  5. 5 MadridSpain 53 works
  6. 6 SeoulSouth Korea 51 works
  7. 7 TokyoJapan 51 works
  8. 8 BostonUnited States 50 works
  9. 9 ShanghaiChina 43 works
  10. 10 BarcelonaSpain 41 works

Where it is the local speciality

  1. Silver SpringUS · 29.8 works30×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Biosimilars and Bioanalytical Methods than the world average.

See Biosimilars and Bioanalytical Methods on the map

Where is the best place to study Biosimilars and Bioanalytical Methods?

Among universities, judged by research, Harvard University, KU Leuven and University of Oslo score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 17.43%fractional works in this field (log) →share of work in the world top 10% →University of OsloUniversity of Gronin…Harvard UniversityKU Leuven
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 80.519.1%3.8×50 +20.5%
2KU LeuvenBelgium 59.216.4%4.4×18 -30.9%
3University of OsloNorway 59.022.2%4.8×13 +2.8%
4University of GroningenNetherlands 58.721.5%2.8×8 +6.3%
5Leiden UniversityNetherlands 56.319.2%4.1×9 +30.8%
6Ghent UniversityBelgium 52.411.6%4.4×14 +14.4%
7Northwestern UniversityUnited States 51.717.7%2.9×10 +112.0%
8University of British ColumbiaCanada 51.316.4%2.9×15 +38.4%
9Erasmus University RotterdamNetherlands 51.016.8%5.6×12 -14.3%
10The University of SydneyAustralia 50.213.4%2.7×14 +220.8%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Biosimilars and Bioanalytical Methods, country by country

Is Biosimilars and Bioanalytical Methods research growing?

Output in 2022-2025 was 15% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Biosimilars and Bioanalytical Methods.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Biosimilars and Bioanalytical Methods as a percentage of every work published that year, 0.021% in 2024.

still counting0.010%0.020%0.030%Biosimilars and Bioanalytical Methods0.021% in 202519801990200020102020

Fractional works of Biosimilars and Bioanalytical Methods over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Biosimilars and Bioanalytical Methods10.0% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Biosimilars and Bioanalytical Methods. Posts are plain text and can be reported.